<DOC>
	<DOCNO>NCT00199147</DOCNO>
	<brief_summary>Aim study compare efficacy intensive induction therapy Cytarabine , Idarubicin Etoposide ( IdAV ) give parallel ( G-CSF priming ) follow G-CSF versus IdAV chemotherapy follow G-CSF ( without prim ) elderly patient de novo AML , secondary AML advance MDS . Moreover , ability mobilize sufficient number peripheral blood stem cell ( PBSC ) autologous PBSC transplantation consolidation therapy dose-reduced FLAG-Ida chemotherapy follow G-CSF evaluate .</brief_summary>
	<brief_title>Efficacy G-CSF-Priming Elderly AML Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Diagnosis denovo AML , FAB M0 , 1 , 2 , 47 Diagnosis secondary AML previous chemotherapy and/or radiation therapy preceeding MDS Diagnosis advance MDS , i.e . RAEBt accord FAB classification Extramedullary AML ( chloroma , “ granulocytic sarcoma ” ) Age great 60 year ( include 60 year ) ECOG performance status 0 , 1 , 2 Written informed consent Patients ( 15 ; 17 ) translocation Patients severe cardiac disease ( e.g . cardiac failure NYHA III/IV , myocardial infarction within last 6 month ; severe ventricular arrythmias ( Lown III IV ) Patients severe complication leukemia uncontrolled bleeding , pneumonia hypoxia shock . Severe pulmonary disease ( diffusion capacity CO2 le 50 % ) Significant renal dysfunction ( creatinine clearance &lt; 60/min/min ) Bilirubin &gt; 2mg % ( &gt; 34.2 mmol/l ) Patients clinically active second malignancy Patients psychiatric , addictive , disorder wich compromise ability give truly informed consent participate study HIV positivity Known refractoriness platelet transfusion , inability adequately substitute blood product</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>